ANTI-CXCR3 ANTIBODIES

• Main Authors: MICHELE YOUD, TIMOTHY D CONNORS, TRACEY LODIE, KAREN B CARTER, CHU RUIYIN, ELIZABETH MASTERJOHN, JENNIFER TEDSTONE, JASON ROBERT PINCKNEY
• Format: Patent
• Language: English; Japanese
• Published: 01.11.2018
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

To provide anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D.SOLUTION: There is provided an antibody or antigen binding fragment capable of binding to CXCR3. The antibody or antigen binding fragment comprises 6 complementarity determining regions (CDRs), namely, heavy chain variable domain (VH) CDR1, VH CDR2, VH CDR3, light chain variable domain (VL) CDR1, VL CDR2, and VL CDR3, each of which includes an amino acid sequence selected from a group consisting of specific amino acid sequences.SELECTED DRAWING: None 【課題】抗ＣＸＣＲ３抗体、ならびに本抗体を使用して糖尿病Ｉ型（Ｔ１Ｄ）、特に初発のＴ１ＤのようなＣＸＣＲ３関連障害を診断および／または処置する方法の提供。【解決手段】ＣＸＣＲ３に結合することができる抗体または抗原結合フラグメントにおいて、該抗体または抗原結合フラグメントは、６つの相補性決定領域（ＣＤＲ）：重鎖可変ドメイン（ＶＨ）ＣＤＲ１、ＶＨ ＣＤＲ２、ＶＨ ＣＤＲ３、軽鎖可変ドメイン（ＶＬ）ＣＤＲ１、ＶＬ ＣＤＲ２、およびＶＬ ＣＤＲ３を含み、各々が特定のアミノ酸配列からなる群から選択される、アミノ酸配列を含む、前記抗体または抗原結合フラグメント。【選択図】なし